The CELsignia Test identifies new targeted therapy options for cancer patients.
CELsignia tests analyze the signaling activity of three important pathways involved in cancer. We use live tumor cells from HER2-negative breast cancer patients to determine if they have one of three cancer sub-types:
- Abnormal HER2 signaling cancer
- Abnormal HER2 and c-Met signaling cancer
- Abnormal PI3K signaling cancer
Pathways with abnormal signaling have CELsignia Scores 5-7 times higher than normal signaling ones. This enables CELsignia Tests to be highly accurate.
Up to 25%-35% of HER2-negative breast patients have a cancer sub-type only a CELsignia test can diagnose.